Marcus O. Butler

16.3k total citations · 3 hit papers
248 papers, 6.9k citations indexed

About

Marcus O. Butler is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Marcus O. Butler has authored 248 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Oncology, 116 papers in Immunology and 67 papers in Molecular Biology. Recurrent topics in Marcus O. Butler's work include Cancer Immunotherapy and Biomarkers (118 papers), CAR-T cell therapy research (96 papers) and Immunotherapy and Immune Responses (81 papers). Marcus O. Butler is often cited by papers focused on Cancer Immunotherapy and Biomarkers (118 papers), CAR-T cell therapy research (96 papers) and Immunotherapy and Immune Responses (81 papers). Marcus O. Butler collaborates with scholars based in Canada, United States and United Kingdom. Marcus O. Butler's co-authors include Naoto Hirano, Tingxi Guo, Lee M. Nadler, F. Stephen Hodi, Kayoko Saso, Mark Anczurowski, Yuki Kagoya, Anthony M. Joshua, Martín C. Mihm and Glenn Dranoff and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Marcus O. Butler

234 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

2003 778 citations F. Stephen Hodi, Marcus O. Butler et al. profile →
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2008 488 citations F. Stephen Hodi, Marcus O. Butler et al. profile →
A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects

2018 446 citations Yuki Kagoya, Shinya Tanaka et al. profile →

Peers

Countries citing papers authored by Marcus O. Butler

Since Specialization

Citations

This map shows the geographic impact of Marcus O. Butler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus O. Butler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus O. Butler more than expected).

Fields of papers citing papers by Marcus O. Butler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcus O. Butler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus O. Butler. The network helps show where Marcus O. Butler may publish in the future.

Co-authorship network of co-authors of Marcus O. Butler

This figure shows the co-authorship network connecting the top 25 collaborators of Marcus O. Butler. A scholar is included among the top collaborators of Marcus O. Butler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcus O. Butler. Marcus O. Butler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure 2025 ·ESMO Open ·Inês Pires da Silva, Lisa Zimmer, Jean‐Yves Blay, Michele Maio, John O. Larkin, Marc‐Oliver Grimm, Isha Puri, Marcus O. Butler, Sapna P. Patel, (unknown), Georgina V. Long, Ignacio Melero	0
2	1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma 2024 ·Annals of Oncology ·Marcus O. Butler, Ryan Weight, Rizwan Haq, (unknown), (unknown), Bartosz Chmielowski, (unknown), Matteo S. Carlino, Meredith McKean, (unknown), Sriram Chandrasekaran, Seema A. Khan, (unknown), Jose Lutzky, Mark Shackleton, (unknown), Darrin M. Beaupre, George W. Cole, Hina Patel, (unknown)	2
3	Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial. 2024 ·Journal of Clinical Oncology ·April A. N. Rose, (unknown), (unknown), (unknown), (unknown), (unknown), Ian King, Tong Zhang, (unknown), Trevor J. Pugh, Marcus O. Butler, Frances A. Shepherd, Philippe L. Bédard, Natasha B. Leighl, Albiruni Ryan Abdul Razak, Aaron R. Hansen, Samuel D. Saibil, Lillian L. Siu, David W. Cescon, Anna Spreafico	2
4	A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301). 2024 ·Journal of Clinical Oncology* ·Georgina V. Long, Victoria Atkinson, Paolo A. Ascierto, Diwakar Davar, Omid Hamid, Caroline Robert, Marcus O. Butler, Reinhard Dummer, Christine Häfner, Muhammad Adnan Khattak, James Larkin, Paul Lorigan, Meredith McKean, (unknown), Heather M. Shaw, Joe Stephenson, Yuan Yuan, (unknown), Piruntha Thiyagarajah, Dirk Schadendorf	3
5	Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors 2024 ·OncoImmunology ·Douglas C. Chung, Maryam Ghaedi, Kathrin Warner, Azin Sayad, Samuel D. Saibil, Marcus Q. Bernardini, Blaise Clarke, Patricia A. Shaw, Marcus O. Butler, Alexandra Easson, A. Sorana Morrissy, Ben X. Wang, Linh T. Nguyen, Pamela S. Ohashi, Nicolas Jacquelot	1
6	1131P Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting 2023 ·Annals of Oncology ·Maria Flávia Marques Ribeiro, (unknown), Elizabeth Koch, (unknown), (unknown), (unknown), (unknown), (unknown), Sofia Genta, Pavlina Spiliopoulou, Olga Vornicova, (unknown), Elisa Giovannetti, Hatem Krema, (unknown), Anna Spreafico, Marcus O. Butler	3
7	Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067. 2023 ·Journal of Clinical Oncology ·F. Stephen Hodi, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, Piotr Rutkowski, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Paola Queirolo, Michael Smylie, Marcus O. Butler, Andrew Hill, Iván Márquez‐Rodas, Corey Ritchings, (unknown), Peter Wang, Jedd D. Wolchok, James Larkin	0
8	Combined autologous blood patch-immediate patient rollover does not reduce the pneumothorax or chest drain rate following CT-guided lung biopsy compared to immediate patient rollover alone 2023 ·European Journal of Radiology ·(unknown), (unknown), Brian O’Riordan, (unknown), Gerard M. Healy, (unknown), Marcus O. Butler, Michael P. Keane, Cormac McCarthy, David J. Murphy, Jonathan D. Dodd	5
9	LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial 2023 ·Annals of Oncology ·Sophie Piperno‐Neumann, (unknown), Piotr Rutkowski, J.F. Baurain, Max Schlaak, Marcus O. Butler, Ryan J. Sullivan, Reinhard Dummer, (unknown), (unknown), (unknown), Sebastian Ochsenreither, Anthony M. Joshua, (unknown), Brendan D. Curti, (unknown), Omid Hamid, Linda Collins, Christopher P. Holland, Paul Nathan	0
10	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Mary L. Disis, Sarah F. Adams, Jyoti Bajpai, Marcus O. Butler, Tyler J. Curiel, (unknown), Laura Doherty, Leisha A. Emens, Claire F. Friedman, Margaret E. Gatti‐Mays, Melissa A. Geller, Amir A. Jazaeri, Veena S. John, Katherine C. Kurnit, John B. Liao, Haider Mahdi, Anne M. Mills, Emese Zsíros, Kunle Odunsi	14
11	The Role of Adjuvant Radiotherapy for the Treatment of Resected High-Risk Stage III Cutaneous Melanoma in the Era of Modern Systemic Therapies 2023 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Xiang Y. Ye, Anna Spreafico, Samuel D. Saibil, A. Sun, (unknown), (unknown), (unknown), Philip Wong, Marcus O. Butler	1
12	2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer 2022 ·International Journal of Gynecological Cancer ·Kathleen N. Moore, Adam Asch, Víctor Moreno, Emiliano Calvo, Marcus O. Butler, Jon Zugazagoitia, David S. Hong, Ahmed M. Galal, (unknown), Maria J. de Miguel, Quan Lin, (unknown), (unknown), (unknown), (unknown), Revashnee Naidoo, Natalie Bath, (unknown), Elliot Norry, Jeffrey Clarke	1
13	Modification of the HLA-A24:02 Peptide Binding Pocket Enhances Cognate Peptide-Binding Capacity and Antigen-Specific T Cell Activation 2022 ·The Journal of Immunology* ·Kenji Murata, Dalam Ly, Hiroshi Saijo, Yukiko Matsunaga, Kenji Sugata, Fumie Ihara, (unknown), (unknown), Kayoko Saso, Chung-Hsi Wang, (unknown), (unknown), Marcus O. Butler, Naoto Hirano	2
14	Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy 2020 ·Cancer Immunology Research ·Yuki Kagoya, Tingxi Guo, Brian Yeung, Kayoko Saso, Mark Anczurowski, Chung-Hsi Wang, Kenji Murata, Kenji Sugata, Hiroshi Saijo, Yukiko Matsunaga, (unknown), Marcus O. Butler, Naoto Hirano	126
15	Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201) 2019 ·Clinical Cancer Research ·Jason J. Luke, Daniel J. Olson, Jacob B. Allred, Carrie Strand, Riyue Bao, Yuanyuan Zha, Timothy Carll, Brian Labadie, Bruno R. Bastos, Marcus O. Butler, David Hogg, Pamela N. Münster, Gary K. Schwartz	43
16	Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221 2019 ·Clinical Cancer Research ·Anna V. Tinker, Holger W. Hirte, Diane Provencher, Marcus O. Butler, (unknown), Dongsheng Tu, Hatem A. Azim, (unknown), (unknown), (unknown), (unknown), Lesley Seymour	70
17	Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma 2018 ·Cancer Immunology Research ·Jeremy Lewin, Scott Davidson, Nathaniel D. Anderson, (unknown), Jacalyn Kelly, Uri Tabori, Samer Salah, Marcus O. Butler, Kyaw Aung, Adam Shlien, Brendan C. Dickson, Albiruni R. Abdul Razak	43
18	Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy 2015 ·Cancer Immunology Research ·Toshiki Ochi, Munehide Nakatsugawa, Kenji Chamoto, Shinya Tanaka, Yūki Yamashita, Tingxi Guo, Hiroshi Fujiwara, Masaki Yasukawa, Marcus O. Butler, Naoto Hirano	29
19	Induction of HLA-DP4–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell 2011 ·Clinical Cancer Research ·Makito Tanaka, Marcus O. Butler, Sascha Ansén, Osamu Imataki, Alla Berezovskaya, Lee M. Nadler, Naoto Hirano	26
20	PROBLEMS OF MISMATCHED BONE-MARROW TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY USING SOY BEAN LECTIN FRACTIONATION 1983 ·UCL Discovery (University College London) ·RJ Levinsky, (unknown), Marcus O. Butler, DC Linch, AH Goldstone	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact